Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b clinical trial of Starget's lead theranostic, DOTA-PTR-58 for sarcomas, neuroendocrine tumors (NET), melanoma, and hepatocellular carcinomas.

Trial Profile

Phase 1b clinical trial of Starget's lead theranostic, DOTA-PTR-58 for sarcomas, neuroendocrine tumors (NET), melanoma, and hepatocellular carcinomas.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 225Ac PTR 58 (Primary)
  • Indications Liver cancer; Malignant melanoma; Neuroendocrine tumours; Sarcoma
  • Focus Adverse reactions

Most Recent Events

  • 29 Apr 2025 The MR mentions The trial will be conducted at MD Anderson and other centers hence I didn't assumed the location for now
  • 29 Apr 2025 New trial record
  • 23 Oct 2024 According to Starget Pharma media release, the company received $5.1 million investment from Cancer Focus Fund to support a Phase 1b clinical trial of DOTA-PTR-58.The trial will be conducted at MD Anderson and other centers and will begin enrolling patients in early 2025.Jordi Rodon will be the Principal Investigator of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top